logo
Most common causes of cavities in the teeth — and how to prevent them

Most common causes of cavities in the teeth — and how to prevent them

Yahoo2 days ago

Cavities are incredibly common, affecting 90% of adults between the ages of 19 and 64 — but they are often preventable.
Also known as "dental caries," cavities are damaged areas in the hard parts of the teeth caused by tooth decay, according to Mayo Clinic.
These areas become tiny openings or holes that can lead to toothaches, infections and even tooth loss.
When a cavity is just starting, you may not have any symptoms at all. That's why it's important to be checked regularly at a dentist, says the Centers for Disease Control and Prevention (CDC).
Even if your mouth feels fine, a professional may be able to pick up on smaller signals before the decay grows.
Is Ozempic Ruining Your Teeth? What To Know About Impact On Dental Health
Read On The Fox News App
Once the decay gets larger, there may be symptoms like toothaches, sharp pains when eating, visible holes in the teeth, staining on the surface of a tooth or pain when biting.
Dental plaque forming in the mouth is what leads to tooth decay, the process that creates cavities.
Plaque forms when bacteria in the mouth mixes with "sugary or starchy food" like milk, juice, bread and pasta, according to Cleveland Clinic.
Fluoride Exposure Linked To 'Detrimental Effects' On Health Of Pregnant Women, Infants
If those sugars and starches are not removed from the teeth through healthy habits, like regular flossing and brushing after meals, bacteria begin feeding on them, the above source states.
The acids from bacteria strip away tooth enamel, leaving tiny openings that mark the beginning stages of a cavity. Bacteria and acid can enter through these holes and reach the vulnerable inner parts of the teeth, causing pain and more severe problems.
Fox News Digital previously spoke to Dr. Ricky Marshall about the impact of stomach acid and saliva production on dental health.
"The amount of acid coming up and contacting the teeth will absolutely contribute to increased tooth decay," said Marshall, who is the owner of Stratland Dental in Glendale, Arizona, and a dentist at Wolff Family Dentistry & Orthodontics in Queen Creek, Arizona.
"A combination of dry mouth and increased stomach acid can be detrimental to teeth," he said.
Brush, Floss, Mouthwash: Dentists Reveal What They Believe Is The Correct Order
Dry mouth, linked to causes like snoring and potentially certain medications, can increase the risk of tooth decay due to reduced saliva production.
"Your saliva clears away the acid and helps to repair the enamel," the CDC states on its website. "If the repair isn't fast enough, bacteria get inside your tooth and make cavities."
Cleveland Clinic recommends brushing your teeth with a soft-bristled brush twice a day, and ideally after every meal.
Click Here To Sign Up For Our Health Newsletter
Experts also recommend cutting back on sugary, starchy foods and drinks. As mentioned above, these can mix with bacteria and promote the buildup of dental plaque.
For more Health articles, visit www.foxnews.com/health
"You should visit your dentist every year, especially to find any cavities," the CDC advises.
For small cavities, your dentist may recommend using fluoride or other products. Large cavities may require fillings or even root canals.Original article source: Most common causes of cavities in the teeth — and how to prevent them

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

At $185, These Samsung Galaxy Buds 3 Pro Just Matched an Amazon All-Time Low
At $185, These Samsung Galaxy Buds 3 Pro Just Matched an Amazon All-Time Low

CNET

time12 minutes ago

  • CNET

At $185, These Samsung Galaxy Buds 3 Pro Just Matched an Amazon All-Time Low

Samsung makes just about everything these days, including some of the best wireless earbuds on the market. The Samsung Galaxy Buds 3 Pro have all the features you'd expect from premium earbuds, and this is your chance to pick a pair up with a $65 discount. Thanks to this Amazon deal, you can currently get these incredible earbuds for just $185. That's the lowest price that we've seen Amazon sell these earbuds for, although it doesn't quite match a previous Woot deal that slashed them even further. That deal was for the international version, though, and you only got a 90-day warranty. Amazon's offer gets you the US version with a full two-year warranty, so that's worth keeping in mind. We can't vouch for how long this deal will last, which means you should definitely consider ordering soon. It's a limited-time deal, so it won't last forever. Hey, did you know? CNET Deals texts are free, easy and save you money. You'll definitely regret missing out if you're too late, too. These earbuds have a redesigned fit, which is said to offer a more comfortable listening experience. They're IPX7 water resistant, so you can use them when out in the rain and whatnot, and the noise cancellation features make them a perfect companion for loud offices and noisy commutes. In terms of battery life, Samsung says you can look forward to up to 8 hours, depending on whether you're using ANC or not, while the included charging case bumps that to 18 hours. Fast-charging tech ensures you can get a battery boost when needed, too. Because of all of this, this is easily one of the best wireless earbuds deals around right now. Why this deal matters Getting great features often means spending great sums of money, which is why we're always keen to share deals like this one. If you'd eyed these wireless earbuds in the past but balked at their $250 price tag, now's your chance to pick them up for less. Just make sure you do it before Amazon calls time on this deal.

Employers Reluctant To Cover Obesity Meds, Lower Costs May Change This
Employers Reluctant To Cover Obesity Meds, Lower Costs May Change This

Forbes

time13 minutes ago

  • Forbes

Employers Reluctant To Cover Obesity Meds, Lower Costs May Change This

A new survey report from the International Foundation of Employee Benefit Plans shows continued reluctance by United States employers to cover glucagon-like peptide-1 drugs for weight loss. Going forward, however, lower net costs may induce better coverage by employers. Makers of GLP-1s for obesity are offering an array of discounts, some to insurers, others directly to patients. The IFEBP first conducted the survey in Oct. 2023 and again in May 2024. In the latest survey released ten days ago, employers revealed that 55% of them provide coverage of GLP-1s for diabetes only, while only 36% provide coverage for both diabetes and weight loss. And of those employers currently offering GLP-1 drug coverage solely for diabetes, just 17% are considering reimbursement of drugs for weight loss. Broadly speaking, the survey responses demonstrate that a large number of employers are still unwilling to reimburse GLP-1s for obesity. The weight loss therapeutics activate the body's receptors for GLP-1 on its own or in combination with GIP. When released by the gut, these natural hormones increase insulin delivery, suppress appetite, slow stomach emptying and increase the feeling of fullness. Perhaps what's driving continued reluctance to cover these products for weight loss is the overall impact that GLP-1s have on employers' pharmacy budgets. GLP-1 drugs used for obesity account for an average of 10.5% of total annual claims in the 2025 survey. In parts of the traditional health plans' market, we observe that some insurers are reconsidering their coverage of GLP-1s. Blue Cross Blue Shield, for example, just announced a reversal in its policy in which some plans offered coverage of GLP-1s for obesity. Starting in January 2026, BCBS will no longer cover these medicines for weight loss across the insurer's standard plans. At the same time, however, the large insurer Cigna announced it will begin capping out-of-pocket costs at $200 per month, starting next month, for patients using the obesity drugs Wegovy (semaglutide) and Zepbound (tirzepatide) through an add-on to its pharmacy benefit management plans. This is aimed at encouraging more employers to offer coverage of the drugs. It's unknown what the net cost to Cigna will be for the medicines. But presumably, the insurer has been able to reach a deal that's favorable financially, meaning a substantial reduction in net costs. It's possible in future that employers decide to revisit their coverage decisions if net costs decrease sufficiently, combined with more data showing the benefits of weight loss drugs when taken consistently and in conjunction with an appropriate dietary and exercise regimen. Also, the pharmaceutical firm Novo Nordisk announced last month a new partnership with CVS Caremark, the nation's largest pharmacy benefit manager, which grants coverage of Wegovy over its competitor Zepbound for customers who are insured for obesity medications. It's presumed that CVS was able to negotiate sizable rebates for Wegovy. CVS Caremark said that for insured patients, starting this July, Wegovy and Saxenda (liraglutide) will be the preferred GLP-1 medicines on its largest commercial formularies. This implies fewer access restrictions such as prior authorization, but also lower patient cost-sharing. It's unknown precisely what this means in terms of out-of-pocket costs for patients. But most patients with coverage for obesity drugs have monthly cost-sharing under $100. The arrangements reached by Cigna and CVS could help bring down net prices for employers for popular weight loss medicines. And at the same time, under the Inflation Reduction Act, the federal government is negotiating the prices of the GLP-1s Ozempic (semaglutide) and Wegovy. So-called maximum fair prices will be publicly posted in early 2026. These could reflect even steeper discounts. In addition to what payers are doing, Novo Nordisk is pursuing a direct-to-patient strategy to regain market share it has lost to drug maker Eli Lilly in the lucrative obesity drug market. Here, Novo Nordisk struck a deal in which CVS pharmacy will offer Wegovy for $499 a month for cash-paying customers who aren't insured for the medication. Since the Food and Drug Administration removed the active ingredients semaglutide and tirzepatide from its shortage list, the business model of selling directly at a considerable discount to the consumer has become popular for the two main manufacturers of obesity drugs. In 2024, Eli Lilly adopted a direct-to-consumer strategy for Zepbound, among other products, with its LillyDirect program. This service includes a DTC pharmacy and a referral network of in-person and telehealth clinicians. LillyDirect allows uninsured or underinsured individuals not on Medicaid or Medicare to purchase Zepbound product directly after obtaining the requisite prescription from their doctor. The firm recently extended the range of Zepbound products available through LillyDirect by adding high-dose vials at $499. Rival Novo Nordisk also launched a DTC option, NovoCare Pharmacy, two months ago. Patients not insured in the public sector who wish to have access to Wegovy can acquire the drug for an out-of-pocket cost of $499 per month, provided they have a prescription and make use of a designated specialty pharmacy. And, since the end of April, customers also pay a $499 monthly subscription when they obtain Wegovy from Ro and LifeMD, and $599 at Hims & Hers. While employers aren't yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future coverage decisions.

Meet the youth challenging Trump on climate
Meet the youth challenging Trump on climate

E&E News

time14 minutes ago

  • E&E News

Meet the youth challenging Trump on climate

Eva Lighthiser, 19, lives in Livingston, Montana, and is accustomed to milelong coal trains rumbling through town and blowing coal dust across the city. In 2023, she was a plaintiff in a youth-led lawsuit that sought to force her state to tackle climate change. Now, she's the lead challenger in Lighthiser v. Trump, a new climate lawsuit that accuses President Donald Trump of violating the Constitution by issuing a trio of executive orders that fast track fossil fuel development. 'Every place is going to be affected by this administration and it's very concerning to see what that will look like moving forward,' Lighthiser said in an interview. Advertisement The case, filed last week in the U.S. District Court for the District of Montana, argues that Trump's executive orders will worsen climate change and increase health dangers by declaring a 'national energy emergency' and directing the government to 'unleash American energy.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store